Compound Monoammonium Glycyrrhizinate Injection
Function and Efficacy
Glycyrrhizic acid monoamine has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone. After use, it shows obvious corticosteroid-like effects, such as anti-inflammatory effects, anti-allergic effects, and protective membrane structures; there are no obvious corticosteroid-like adverse reactions. This product can promote monochrome metabolism, reduce the release of ALT and AST; induce γ-IFN and interleukin II, increase NK cell activity and OKT4/OKT8 ratio and activate the reticuloendothelial system; inhibit mast cell release of histamine; inhibit the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reactions; inhibit the production and formation of free radicals and lipid peroxides, and reduce the activity of proline hydroxylase; regulate calcium ion channels, protect lysosomal membranes and mitochondria
Ingredients
This product is a compound preparation, and its components are: each 1 ml contains 2 mg of monoammonium glycyrrhizinate (C42H65NO16·2H2O), 1.5 mg of L-cysteine hydrochloride (C3H7NO2S·HCl·H2O), and 20 mg of glycine (C2H5NO2).
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Glycyrrhizic acid ammonium saltIngredients |
It has a strong affinity for steroid metabolic enzymes in the liver, thereby hindering the inactivation of cortisol and aldosterone, showing obvious corticosteroid-like effects (such as anti-inflammatory, anti-allergic and protective membrane structure), promoting monochromatic metabolism, reducing the release of ALT and AST; inducing γ-IFN and interleukin II, increasing NK cell activity and the OKT4/OKT8 ratio and activating the reticuloendothelial system; inhibiting the production and formation of free radicals and lipid peroxides, reducing the activity of proline hydroxylase; regulating calcium ion channels, protecting lysosomal membranes and mitochondria More |
53956-04-0 | 8 | |
| L-Cysteine hydrochloride monohydrateIngredients |
Inhibits the release of histamine from mast cells; inhibits the formation of cell membrane phospholipase A2 (PL-A2) and prostaglandin E2 (PGE2) and granulomatous reaction More |
7048-04-6 | 4 | |
| GlycineIngredients |
No specific mention of pharmacological effects More |
56-40-6 | 27 |
Indication
It is used for abnormal liver function caused by acute and chronic hepatitis; it has a certain auxiliary therapeutic effect on toxic hepatitis. It can also be used for food poisoning, drug poisoning, drug allergy, etc.
Usage and Dosage
Intravenous drip. 20-80 ml at a time, add 5% glucose or 0.9% sodium chloride 250-500 ml injection solution to dilute, and slowly drip. Once a day. Intravenous injection. 20-80 ml at a time, add an equal amount of 5% glucose injection solution, and slowly push intravenously. Once a day.
Adverse Reactions
Poor appetite, nausea, vomiting, abdominal distension, itchy skin, urticaria, dry mouth and edema, water and sodium retention, hypokalemia, pseudoaldosteronism, common headache, dizziness, palpitations and increased hypertension in the cardiovascular and cerebrovascular system. The above symptoms are generally mild and do not affect treatment. Occasionally, chest tightness, thirst and allergic reactions may occur.
Precautions
1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe hypokalemia and hypernatremia are prohibited from using this product. 3. Patients with hypertension and heart failure are prohibited from using this product. 4. Patients with renal failure are prohibited from using this product. 5. Patients with aldosteronism and tumors are prohibited from using this product.
Drug Interactions
Hypokalemia is likely to occur when used in combination with furosemide (Lasix) or thiazide diuretics.
Storage
Keep tightly closed in a cool, dark place.
Packaging Specification
20ml
Manufacturer
Anhui Changjiang Pharmaceutical Co., Ltd.
-
Founded in:
2001-12-25 -
Address:
No. 152, Changjiang South Road, High-tech Industrial Development Zone, Wuhu City, Anhui Province (declaration commitment) -
Tax NO.:
91340200733036887Q -
Registered Funds:
82.35294118 million yuan -
Website:
-
Email: